Figure 2:

Adjusted odds ratios for medication for opioid use disorder initiation among pregnant versus nonpregnant reproductive-aged women with opioid use disorder. Model 1: Logistic regression models showing the odds of buprenorphine initiation associated with pregnant (n=2,687) compared with nonpregnant people (n=99,084), controlling for age, insurance status, co-occurring substance use disorders (alcohol, cannabis, sedative, stimulant, tobacco), co-occurring anxiety disorders, co-occurring psychotic disorders, and co-occurring mood (bipolar, major depression) disorders. Model 2: Logistic regression models showing the odds of methadone initiation associated with pregnant (n=2,243) compared with nonpregnant people (n=63,313), controlling for age, race (data only available for Medicaid enrollees), co-occurring substance use disorders (alcohol, cannabis, sedative, stimulant, tobacco), co-occurring anxiety disorders, co-occurring psychotic disorders, and co-occurring mood (bipolar, major depression) disorders. Model 3: Logistic regression models showing the odds of methadone initiation associated with pregnant (n=2,687) compared with nonpregnant people (n=99,084), controlling for age, insurance status, co-occurring substance use disorders (alcohol, cannabis, sedative, stimulant, tobacco), co-occurring anxiety disorders, co-occurring psychotic disorders, and co-occurring mood (bipolar, major depression) disorders. Model 4: Logistic regression models showing the odds of methadone initiation associated with pregnant (n=2,243) compared with nonpregnant people (n=63,313), controlling for age, race (data only available for Medicaid enrollees), co-occurring substance use disorders (alcohol, cannabis, sedative, stimulant, tobacco), co-occurring anxiety disorders, co-occurring psychotic disorders, and co-occurring mood (bipolar, major depression) disorders.